Under the terms of this agreement, Magellan Bioscience Group, Inc. will provide to Thrombotargets its compounds and extracts from fermentation broths of marine-isolated microorganisms to be screened through the revolutionary High Throughput Screening of Pathway Activity, BIOPLATFORMSCREEN™ technology. This modified HTS platforms allows to both Thrombotargets and partners to identify novel hits for entire Pathways regulating a certain biological activity.
